<DOC>
	<DOCNO>NCT01545375</DOCNO>
	<brief_summary>The purpose study 1 ) demonstrate protective efficacy acute otitis medium ( AOM ) , 2 ) ass safety GlaxoSmithKline ( GSK ) Biologicals ' pneumococcal vaccine GSK2189242A Native American infant age less 24 month , live southwestern US , around Navajo White Mountain Apache reservation , 3 ) evaluate impact acute low respiratory tract infection ( ALRI ) second year life .</brief_summary>
	<brief_title>Evaluation Vaccine Reducing Ear Lung Infections Children</brief_title>
	<detailed_description>The study also evaluate impact pneumococcal vaccine GSK2189242A nasopharyngeal carriage subgroup child call Carriage subgroup . Immunogenicity reactogenicity pneumococcal vaccine GSK2189242A evaluate another subgroup child call Immuno/reacto subgroup .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subject investigator believe parent ( ) /Legally Authorized Representative ( ) ( LARs ) comply requirement protocol . A male female American Indian infant , include , 6 12 week ( 4290 day ) age time first vaccination . Voluntary , write informed consent obtain parents/LAR ( ) subject . Where parent ( ) /LAR ( ) illiterate , consent form countersign witness . Healthy subject establish medical history clinical examination enter study . Born gestation period 35 6/7 week . For infant : Child care . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Planned administration/administration vaccine foreseen study protocol start 30 day dose end 30 day dose study vaccine , exception license inactivated influenza vaccine recommend pediatric vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Previous vaccination S. pneumoniae . Obstruction anomalies nasopharyngeal space . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine ( ) include latex . Major congenital defect serious chronic illness . History neurological disorder seizure . Acute disease and/or fever time enrollment . Administration immunoglobulins and/or blood product since birth plan administration study period . Any medical social condition might interfere assessment study objective opinion investigator . For infant Immuno/reacto subgroup : â€¢ Previous vaccination H. influenzae type b .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>nasopharyngeal carriage</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>US</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>efficacy</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>infant</keyword>
</DOC>